Elsevier

Contraception

Volume 74, Issue 5, November 2006, Pages 359-366
Contraception

Review article
Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives

https://doi.org/10.1016/j.contraception.2006.06.003Get rights and content

Abstract

As many as 80% of reproductive-aged women experience physical changes associated with menstruation, and 20% to 40% experience menstrual-cycle-related symptoms. Decades of research in women with menstrual disorders, such as dysmenorrhea and menorrhagia, have shown that continuous use of oral contraceptives (OCs), without the hormone-free interval, is a safe and effective method to relieve these symptoms and ultimately induce amenorrhea in many women. If given the opportunity, a majority of women would opt for extended-cycle or continuous regimens, and numerous clinical trials have shown that continuous OC regimens induce amenorrhea in 80% to 100% of women by 10 to 12 months of use. For women who do not wish to become pregnant, a continuous OC regimen should be an available option.

Introduction

Menstruation has an important impact on quality of life for many women, ranging from a simple inconvenience to a major health concern for those suffering from menstrual disorders and conditions that are aggravated during menstruation [1]. Up to 80% of reproductive-aged women experience physical changes associated with menstruation, and 20% to 40% experience menstrual-cycle-related symptoms [2]. Recognized menstrual-cycle-related disorders affect approximately 2.5 million women between the ages of 18 and 50 years in the United States alone [3].

Menstrual-cycle-related symptoms contribute significantly to health care costs due to the number of patients accessing the health care system for diagnosis and therapy. Sixty-five percent of women with menstrual disorders in one retrospective study (N=1666) reported having contacted their physician [3]. Furthermore, 12% of emergency room visits have been attributed to gynecologic disorders in women 15 to 44 years of age, based on results from the National Hospital Ambulatory Medical Care survey [4]. It is encouraging to note that women are seeking treatment for these problems, but these statistics underestimate the prevalence of menstruation-associated symptoms. Only 22% of 19-year-old women in one study (N=596) had sought medical attention for dysmenorrhea, although 72% suffered from various degrees of menstrual-cycle-related pain and nearly 40% required regular analgesics or antispasmodics [5].

Menstruation and menstrual disorders have a broader economic impact on women and society, which is a direct result of time lost from work and decreased productivity [1]. Texas Instruments noted a 25% reduction in the productivity of female workers during menses as one example [6]. The total economic cost of menstrual disorders in the United States is estimated to be 8% of total wages, with dysmenorrhea alone estimated at US$2 billion annually [7] and menorrhagia estimated at US$1692.00 annually per woman [8].

Many women, when given the choice, would eliminate or reduce the frequency of their menses [9], [10], [11]. Medically induced amenorrhea relieves many menstrual-cycle-related symptoms and menstrual disorders. Amenorrhea strictly defined is the absence of menses in menarcheal women. The lack of withdrawal bleeding associated with cessation or interruption of the exogenous steroids contained in oral contraceptives (OCs) will be considered as amenorrhea for this review. Continuous use of OCs, without the usual hormone-free week each cycle, has been used for decades to safely and effectively suppress menses or bleeding for the management of dysmenorrhea and menorrhagia [12]. This review will discuss the impact of menstrual disorders, symptoms and associated conditions on women and the evidence in support of the safe induction of amenorrhea with continuous OC use.

Section snippets

The prevalence and impact of menstrual-cycle-related conditions and symptoms

A plethora of symptoms and pathologies are associated with or exacerbated by menstruation. Measurement or quantification of many of these symptoms and conditions is difficult or impossible, and subjective indices are used in assessing the resultant disability.

The physiology of menstruation and hormone withdrawal

Menstruation has a single biological purpose: to allow the endometrium to be reprogrammed for implantation of a fertilized ovum. In a normal menstrual cycle (i.e., without exogenous hormones), estrogen from the ovaries promotes endometrial growth, a surge in LH from the pituitary results in the release of a mature ovum from the ovary and progesterone is secreted from the corpus luteum. The corpus luteum maintains progesterone production in the luteal phase of the cycle, and if pregnancy occurs,

Clinical experience in reducing menstrual frequency

Since the early days of OC use, studies about reducing the number of pill-free periods have shown that it is a safe and effective option for many women. Because each study has used different OC formulations, with different intervals between pill-free periods, retrospective comparison of these regimens is difficult. The earliest such study, conducted by Loudon et al. [56] in 1977, reduced the withdrawal bleed frequency to once every 3 months (84 days of continuous pills) in 196 women using a

Health and quality-of-life benefits associated with elimination of the menstrual cycle

Many women derive health and quality-of-life benefits by eliminating their menstrual cycle, which may reduce the occurrence of menstrual-cycle-related disorders such as menorrhagia, dysmenorrhea and anemia [1].

Cyclic OC use is already known to improve quality of life. A beneficial effect on psychological general well-being (assessed using the Psychological General Well-Being Index) was observed by Cycle 3 in women using an OC that contained 3 mg drospirenone and 30 μg EE in a 28-day cyclic

Summary

Menstruation can be a major cause of morbidity and suffering in women and can exacerbate other disorders. For many women, continuous regimens of combination OCs are already used to alleviate their symptoms and induce amenorrhea. In addition, some women choose to prolong their 28-day cycles for major life events, such as honeymoons and vacations. Studies have clearly shown that many women would like to reduce the frequency of menstruation or eliminate menstruation altogether. The popularity of

Acknowledgments

The manuscript was initially written under a contract with a medical education company. Mr. Jason McDonough provided the first draft of the manuscript and is acknowledged in the manuscript. The principal author, David F. Archer, M.D., has made extensive changes, corrections and additions to the original manuscript without help from the medical education company. Wyeth was the commercial sponsor of the first draft. David F. Archer, M.D., has not received any payment from Wyeth, nor are there any

References (82)

  • I.S. Fraser et al.

    A preliminary study of factors influencing perception of menstrual blood loss volume

    Am J Obstet Gynecol

    (1984)
  • D.A. Minjarez et al.

    Abnormal uterine bleeding in adolescents

    Obstet Gynecol Clin North Am

    (2000)
  • S. Svalheim et al.

    Do women with epilepsy have increased frequency of menstrual disturbances?

    Seizure

    (2003)
  • J.H. Strathy et al.

    Endometriosis and infertility: a laparoscopic study of endometriosis among fertile and infertile women

    Fertil Steril

    (1982)
  • J.E. Carter

    Combined hysteroscopic and laparoscopic findings in patients with chronic pelvic pain

    J Am Assoc Gynecol Laparosc

    (1994)
  • L. Demco

    Mapping the source and character of pain due to endometriosis by patient-assisted laparoscopy

    J Am Assoc Gynecol Laparosc

    (1998)
  • S.D. Silberstein et al.

    Sex hormones and headache

    J Pain Symptom Manage

    (1993)
  • K. Thomas et al.

    Inhibition of ovulation by low-dose monophasic contraceptive containing gestodene

    Am J Obstet Gynecol

    (1990)
  • H.J. Hoogland et al.

    Ultrasound evaluation of ovarian activity under oral contraceptives

    Contraception

    (1993)
  • C. Egarter et al.

    Ovarian function during low-dose oral contraceptive use

    Contraception

    (1995)
  • J. Spona et al.

    Shorter pill-free interval in combined oral contraceptives decreases follicular development

    Contraception

    (1996)
  • J. Spona et al.

    Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol

    Contraception

    (1996)
  • W.G. Rossmanith et al.

    A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity

    Contraception

    (1997)
  • H. Sullivan et al.

    Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity

    Fertil Steril

    (1999)
  • R.A. Pierson et al.

    Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error

    Fertil Steril

    (2003)
  • C.J. Hamilton et al.

    Longitudinal ultrasonographic study of the ovarian suppressive activity of a low-dose triphasic oral contraceptive during correct and incorrect pill intake

    Am J Obstet Gynecol

    (1989)
  • R.L. Birtch et al.

    Ovarian follicular dynamics during conventional vs. continuous oral contraceptive use

    Contraception

    (2006)
  • E.B. Connell

    Contraception in the prepill era

    Contraception

    (1999)
  • F.D. Anderson et al.

    A multicenter, randomized study of an extended cycle oral contraceptive

    Contraception

    (2003)
  • F.D. Anderson et al.

    Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen

    Contraception

    (2005)
  • L. Miller et al.

    Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial

    Obstet Gynecol

    (2001)
  • M. Kwiecien et al.

    Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial

    Contraception

    (2003)
  • R.B. Machado et al.

    Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 μg) and gestodene (75 μg)

    Contraception

    (2004)
  • L. Miller et al.

    Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial

    Obstet Gynecol

    (2003)
  • M.J. Rosenberg et al.

    Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons

    Am J Obstet Gynecol

    (1998)
  • P. Vercellini et al.

    Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen

    Fertil Steril

    (2003)
  • P.J. Sulak et al.

    Hormone withdrawal symptoms in oral contraceptive users

    Obstet Gynecol

    (2000)
  • P.J. Sulak et al.

    Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms

    Am J Obstet Gynecol

    (2002)
  • M.B. Schneider et al.

    Menstrual and premenstrual issues in female military cadets: a unique population with significant concerns

    J Pediatr Adolesc Gynecol

    (1999)
  • A.J. Davis

    Advances in contraception

    Obstet Gynecol Clin North Am

    (2000)
  • A.M. Kaunitz

    Oral contraceptive use in perimenopause

    Am J Obstet Gynecol

    (2001)
  • Cited by (66)

    • Long-term safety of extended levonorgestrel-containing oral contraceptives in the United States

      2022, Contraception
      Citation Excerpt :

      Approved in the United States (US) in 2006, Seasonique (Theramex, UK), a 91-day extended combined oral contraceptive (COC) of levonorgestrel (LNG) and ethinyl estradiol (EE) (91-day COCLNG), was developed to reduce estrogen-related withdrawal symptoms associated with traditional 28-day COCs, such as headaches, bloating, and pelvic pain. Similar to other extended- or continuous-COC regimens, it was also designed to improve adherence by providing treatment continuity and to decrease scheduled withdrawal bleeding to four episodes per year [1, 2]. The use of COCs is a known risk factor for venous thromboembolism (VTE).

    • Abnormal Uterine Bleeding including coagulopathies and other menstrual disorders

      2018, Best Practice and Research: Clinical Obstetrics and Gynaecology
    • A Review of Hormonal Contraception and Venous Thromboembolism in Adolescents

      2016, Journal of Pediatric and Adolescent Gynecology
      Citation Excerpt :

      Medically complicated adolescents are often prescribed HC because HC-associated VTE risk is generally outweighed by pregnancy-associated risks.58 Menstrual suppression is often sought for adolescent women with various chronic medical conditions (eg, cancer, bleeding disorders, catamenial epilepsy, catamenial headaches, and developmental delay).59–62 Many chronic medical conditions bear an increased VTE risk at baseline, and adolescents with chronic medical conditions are often excluded from HC clinical studies.

    • Hormonal Contraception

      2015, Williams Textbook of Endocrinology
    View all citing articles on Scopus
    View full text